Search
Acoramidis
go.drugbank.com/drugs/DB17999ApprovedInvestigational[L51958] Similar to the previously developed [tafamidis], acoramidis is used to stabilize TTR in its tetrameric form, preventing the formation of amyloidogenic monomers and the progression of amyloidosis … Acoramidis is a small molecule stabilizer of transthyretin (TTR) for use in patients with TTR amyloidosis.
Raloxifene
go.drugbank.com/drugs/DB00481ApprovedInvestigational[A4979,T28] Exhibiting tissue-specific effects distinct from [estradiol], raloxifene is the first of the benzothiophene group of antiestrogens to be labelled a SERM. … [A4977] Available in many countries worldwide, raloxifene was initially approved by the FDA in December, 1997 under the market name Evista® for the management and prevention of osteoporosis in postmenopausal
Paritaprevir
go.drugbank.com/drugs/DB09297ApprovedInvestigationalFirst approved in January 2015, Holkira Pak is indicated for the treatment of HCV genotype 1b with or without cirrhosis, and when combined with [DB00811] for the treatment of HCV genotype 1a with or without … First approved in December 2014, Viekira Pak is indicated for the treatment of HCV genotype 1b without cirrhosis or with compensated cirrhosis, and when combined with [DB00811] for the treatment of HCV
Categories: Antivirals for Systemic Use, Antiinfectives for Systemic UseSetmelanotide
go.drugbank.com/drugs/DB11700ApprovedInvestigationalSetmelanotide is the first available treatment for patients with pro-opiomelanocortin, proprotein subilisin/kexin type 1, or leptin deficiencies. … [A224449] Earlier attempts at agonizing MC4R (such as LY2112688) lead to successful weight loss, but also an increase in blood pressure and heart rate.
Treprostinil
go.drugbank.com/drugs/DB00374ApprovedInvestigationalThe first generic form of treprostinil became available in 2019.[A248775] … Treprostinil was approved by the FDA in 2002 for the treatment of pulmonary arterial hypertension.
Danaparoid
go.drugbank.com/drugs/DB06754ApprovedWithdrawnDanaparoid sodium is the common salt form in therapeutic preparations and is typically administered subcutaneously. … It is chemically distinct from heparin by containing different protein binding properties, thus has lower cross-reactivity in heparin-intolerant patients.
Sevabertinib
go.drugbank.com/drugs/DB21667ApprovedInvestigationalSevabertinib is a kinase inhibitor indicated for adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain … [L54638] It was granted accelerated approval by the FDA on November 19th, 2025.[L54608]
Categories: MATE 2-K InhibitorsEstrone
go.drugbank.com/drugs/DB00655ApprovedIt is produced in vivo from androstenedione or from testosterone via estradiol. … Estrone may be further metabolized to 16-alpha-hydroxyestrone, which may be reduced to estriol by estradiol dehydrogenase.
Metamfetamine
go.drugbank.com/drugs/DB01577ApprovedIllicitInvestigationalWithdrawnThe FDA withdrew its approval for the use of all parenteral drug products containing methamphetamine hydrochloride, a metamfetamine salt.[L43942] … It is a scheduled drug in most countries due to its high potential for addiction and abuse.
Categories: Psychostimulants, Agents Used for ADHD and Nootropics, Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substratesYohimbine
go.drugbank.com/drugs/DB01392ApprovedInvestigationalVet approvedWithdrawnA plant alkaloid with alpha-2-adrenergic blocking activity. Yohimbine has been used as a mydriatic and in the treatment of impotence. It is also alleged to be an aphrodisiac.